✨ Free AI Report
LEXICON PHARMACEUTICALS, INC.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research LEXICON PHARMACEUTICALS, INC.
Company Research

LEXICON PHARMACEUTICALS, INC.: Business Overview, Financials & Competitive Analysis

LEXICON PHARMACEUTICALS, INC. is a pioneering biotechnology company dedicated to discovering and developing breakthrough treatments for a range of human diseases. Founded in 1995, the company has...

Analyst-debate audio for LEXICON PHARMACEUTICALS, INC.

AskCyborg analysts argue the bull and bear cases for LEXICON PHARMACEUTICALS, INC. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Company Overview of LEXICON PHARMACEUTICALS, INC.Product Portfolio of LEXICON PHARMACEUTICALS, INC.LEXICON PHARMACEUTICALS, INC. Leadership and Management TeamFinancial Overview of LEXICON PHARMACEUTICALS, INC.Marketing Strategies of LEXICON PHARMACEUTICALS, INC.LEXICON PHARMACEUTICALS, INC. Market Research and Competitors
Get Interactive Report Freeor start reading below
Live on AskCyborg
6/10Solid
Lexicon Pharmaceuticals, Inc.

Risk-reward turnaround play dependent on successful Phase 3 completion and regulatory approvals for pilavapadin and sotagliflozin in target indications.

▶︎ Listen to the 90-second analyst debate
6/ 10Solid

Cyborg Score thesis

Risk-reward turnaround play dependent on successful Phase 3 completion and regulatory approvals for pilavapadin and sotagliflozin...

Read the full analyst-debate transcript →
Industry Biopharmaceutical / Pharmaceutical Development
3 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: August 17, 2026
AI-Verified Research
30+ Page Report

Get the Latest LEXICON PHARMACEUTICALS, INC. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

LEXICON PHARMACEUTICALS, INC. is a pioneering biotechnology company dedicated to discovering and developing breakthrough treatments for a range of human diseases. Founded in 1995, the company has carved a niche in the pharmaceutical sector through its innovative approach to drug discovery and development. With a strong focus on gene technology, LEXICON PHARMACEUTICALS, INC. has been at the forefront of leveraging genomics to identify and validate drug targets, leading to the development of novel therapies that address unmet medical needs.

Company Overview of LEXICON PHARMACEUTICALS, INC.

Pro stress-test →

LEXICON PHARMACEUTICALS, INC. is headquartered in The Woodlands, Texas, and has a robust pipeline of products aimed at treating a variety of conditions, including rare diseases, diabetes, and cancer. The company’s mission is to transform patients’ lives by developing innovative medicines based on pioneering science.

Product Portfolio of LEXICON PHARMACEUTICALS, INC.

Pro stress-test →

LEXICON PHARMACEUTICALS, INC. has a diverse product portfolio that includes both marketed products and a strong pipeline of drugs in various stages of development:

  • XERMELO®: A treatment for carcinoid syndrome diarrhea in patients with metastatic neuroendocrine tumors.
  • Sotagliflozin: An investigational dual SGLT1 and SGLT2 inhibitor for the treatment of type 1 and type 2 diabetes.
  • Telotristat Ethyl: A therapy in development for the treatment of biliary tract cancer and other rare diseases.

LEXICON PHARMACEUTICALS, INC. Leadership and Management Team

Pro stress-test →

The leadership team at LEXICON PHARMACEUTICALS, INC. includes experienced professionals with extensive backgrounds in the pharmaceutical and biotechnology industries:

  • Lonnel Coats: President and CEO
  • Jeffrey L. Wade, J.D.: Executive Vice President, Corporate and Administrative Affairs and Chief Financial Officer
  • Pablo Lapuerta, M.D.: Executive Vice President and Chief Medical Officer

Financial Overview of LEXICON PHARMACEUTICALS, INC.

LEXICON PHARMACEUTICALS, INC. has demonstrated strong financial performance with strategic investments in research and development. Key financial metrics include:

  • Revenue: $42 million (2022)
  • R&D Expenditure: $78 million (2022)
  • Market Capitalization: Approximately $300 million (as of Q3 2023)

Marketing Strategies of LEXICON PHARMACEUTICALS, INC.

The company employs targeted marketing strategies to reach healthcare professionals and patients. These include:

  • Educational campaigns to raise awareness about their products.
  • Collaborations with patient advocacy groups.
  • Digital marketing strategies to enhance online presence.

LEXICON PHARMACEUTICALS, INC. Market Research and Competitors

LEXICON PHARMACEUTICALS, INC. operates in a highly competitive market with key competitors including:

  • Novartis
  • Eli Lilly
  • Sanofi

The company differentiates itself through its unique approach to drug discovery, leveraging its proprietary gene technology platform.

Sales Strategies of LEXICON PHARMACEUTICALS, INC.

The company’s sales strategies include:

  • Direct sales teams targeting healthcare providers.
  • Partnerships with pharmaceutical distributors.
  • Utilizing digital platforms to reach a broader audience.

Technologies Utilized by LEXICON PHARMACEUTICALS, INC.

LEXICON PHARMACEUTICALS, INC. employs advanced technologies such as:

  • Gene knockout technology to identify drug targets.
  • High-throughput screening for drug discovery.
  • Biomarker development for personalized medicine.

HR Practices at LEXICON PHARMACEUTICALS, INC.

The company values its employees and has implemented several HR practices to ensure a positive work environment:

  • Comprehensive benefits packages.
  • Continuous learning and development programs.
  • Diversity and inclusion initiatives.

Corporate Social Responsibility of LEXICON PHARMACEUTICALS, INC.

LEXICON PHARMACEUTICALS, INC. is committed to corporate social responsibility, with initiatives focused on:

  • Environmental sustainability.
  • Community engagement and philanthropy.
  • Ethical business practices.

Future Plans of LEXICON PHARMACEUTICALS, INC.

The company has ambitious plans for the future, including:

  • Expanding its product pipeline with new drug candidates.
  • Entering new therapeutic areas.
  • Strengthening global market presence.

For a more comprehensive analysis and detailed insights into LEXICON PHARMACEUTICALS, INC., consider purchasing our full research report available at AskCyborg.com. Our detailed report covers extensive market research, financial analysis, and strategic insights that will provide you with a deeper understanding of the company’s operations and future prospects.


Get your report on LEXICON PHARMACEUTICALS, INC. by subscribing

What the analysts stress-tested

The top findings that survived the multi-agent debate for LEXICON PHARMACEUTICALS, INC..

+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

Get alerted when LEXICON PHARMACEUTICALS, INC. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

SGLT2 Inhibitors & GLP-1 AgonistsEstablished therapies in cardio-metabolic spaceGene Therapy PlatformsCompeting precision medicine approachesRare Disease TherapeuticsLate-stage biotech competitors in specialized indications

Compare LEXICON PHARMACEUTICALS, INC. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

LEXICON PHARMACEUTICALS, INC. operates in Biopharmaceutical / Pharmaceutical Development. See how the rest of the sector scores on the Cyborg framework.

Browse Biopharmaceutical / Pharmaceutical Development research →
NEW · MCP server

Ask your AI assistant about LEXICON PHARMACEUTICALS, INC.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare LEXICON PHARMACEUTICALS, INC. and its top competitor on Cyborg Score”
“What did LEXICON PHARMACEUTICALS, INC. do this quarter?”
“Is LEXICON PHARMACEUTICALS, INC. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does LEXICON PHARMACEUTICALS, INC. do?+
LEXICON PHARMACEUTICALS, INC. is a pioneering biotechnology company dedicated to discovering and developing breakthrough treatments for a range of human diseases. Founded in 1995, the company has...
What is LEXICON PHARMACEUTICALS, INC.'s Cyborg Score?+
LEXICON PHARMACEUTICALS, INC. has a Cyborg Score of 6/10 (Solid). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are LEXICON PHARMACEUTICALS, INC.'s main competitors?+
Named competitors include SGLT2 Inhibitors & GLP-1 Agonists, Gene Therapy Platforms, Rare Disease Therapeutics. The full competitive landscape is in the AskCyborg report.
How can I get the full LEXICON PHARMACEUTICALS, INC. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the LEXICON PHARMACEUTICALS, INC. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track LEXICON PHARMACEUTICALS, INC. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Company Research

Gambling and Lotteries Industry BriefingStationery and Office Products Industry BriefingDefense Tech Industry BriefingAi Infrastructure Systems Industry BriefingPet Insurance Industry BriefingSelf-Storage Industry BriefingMetal Additive Manufacturing Industry BriefingAi Accelerator Hardware Systems Industry BriefingLuxury Wines & Spirits Industry BriefingEnzymatic Plastic Recycling Industry BriefingInfrastructure as a Service (IaaS) Industry Briefingluxury fashion apparel Industry Briefing

Explore Industry Research

Travel Insurance Industry Company Research ReportSecurity Services Industry Company Research ReportLandscaping and Grounds Maintenance Industry Company Research ReportJanitorial and Cleaning Services Industry Company Research ReportSustainability Consulting Industry Company Research ReportReal Estate Investment Trusts (REITs) Industry Company Research Report
Browse All Company ResearchBrowse All Industry ResearchRSS Feed